Cite
HARVARD Citation
Maggiolo, F. et al. (2020). Rilpivirine plus cobicistat-boosted darunavir as a two-drug switch regimen in HIV-infected, virologically suppressed subjects on steady standard three-drug therapy: a randomized, controlled, non-inferiority trial (PROBE 2). Journal of antimicrobial chemotherapy. pp. 1332-1337. [Online].